Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Dilip Davda has given "May Apply" recommendation to Maitreya Medicare Limited IPO.
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 1 | 0 | 0 | 0 |
| % | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 |
| Reviewer | Recommendation | Past Reviews |
|---|---|---|
| Dilip Davda | May Apply |  |
[Dilip Davda] The company is operating 125 bed hospitals with multi-speciality healthcare services. It posted declining trends in its top lines, but surprisingly reported improved bottom lines from FY23 onward i.e. in a pre-IPO period. The issue appears fully priced based on its recent financial performance which discounts all near term positives. The small post-IPO equity capital indicates longer gestation for migration to mainboard. Well-informed investors may park funds for medium to long-term rewards. Read detail review...
Maitreya Medicare Limited peer comparison with similar listed entities. () (As on October 20, 2023)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | |
|---|---|---|---|---|---|
| EPS Basic | EPS Diluted | ||||
| Maitreya Medicare Limited | 7.93 | 7.93 | 17.42 | 45.49 | |
| Shalby Limited | 7.48 | 7.48 | 35.35 | 7.30 | |
| KMC Speciality Hospitals (India) Limited | 1.64 | 1.64 | 51.53 | 23.51 | |
| Global Health Limited | 12.57 | 12.57 | 61.76 | 13.43 | |
Notes:
i. Source: All the financial information for listed industry peers mentioned above is sourced from the financial results of the aforesaid companies for the year ended March 31, 2023 and stock exchange data dated Sept 30, 2023 to compute the corresponding financial ratios. Current Market Price is as on 19th October, 2023. For the company, they have taken Current Market Price as the issue price of equity share. Further, P/E ratio is based on the current market price of the respective scrips.
ii. The EPS, NAV, RoNW and Total Income of our company are taken as per Restated Financial Statement for the Financial year 2022-2023.
iii. NAV per share is computed as the closing net worth divided by the weighted average number of paid-up equity shares as on March 31, 2023.
iv. RoNW has been computed as net profit after tax divided by closing networth.
v. Net worth has been computed in the manner as specified in Regualtion 2(1) (hh) of SEBI (ICDR) Regulations, 2018.
Maitreya Medicare Limited IPO Reviews, analysis and views by popular members. Read Maitreya Medicare Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 3 | 0 | 0 | 0 |
| % | 100.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| SMEmitra |
Apply for Short Term at Cut-off Price Parameter - Score (0-5) |
| Priyanka Meghwal |
Apply for Listing Gain at Cut-off Price Reasonable valuation, gud growth prospects, small size IPO with anchor.. |
IPO LEADER  IPO Mentor (800+ Posts, 400+ Likes) |
Apply for Listing Gain at Upper Price Band Decent listing gain possible October 22, 2023 3:41:57 PM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
